Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Rhea-AI Summary

Labcorp (NYSE: LH) and Illumina on March 18, 2026 expanded a collaboration to broaden precision oncology testing access via distributed IVD kits, new CGP and WGS test development, and evidence generation to support payer coverage.

Plans include exploring co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive, and continuing joint studies (one evaluated >7,600 NSCLC samples, detecting actionable variants in >72%).

Positive

• CGP detected actionable variants in >72% of 7,600 NSCLC samples
• Co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive
• Distributed IVD offering intended to expand testing access in hospitals and community systems

Negative

• Execution risk from developing and launching new technologies
• Reliance on partner performance and multiparty collaboration complexity
• Payer coverage remains uncertain despite planned evidence-generation efforts

News Market Reaction – LH

-1.77%

1 alert

-1.77% News Effect

On the day this news was published, LH declined 1.77%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

NSCLC tumor samples: more than 7,600 samples Actionable variant rate: more than 72% of patient tumors Joint oncology publications: 8 publications +1 more

4 metrics

NSCLC tumor samples more than 7,600 samples Non-small cell lung cancer study using Illumina CGP

Actionable variant rate more than 72% of patient tumors Tumors with a variant linked to a targeted therapy or clinical trial

Joint oncology publications 8 publications Joint oncology publications between Illumina and Labcorp since 2022

Posters and presentations 18 posters and presentations Oncology-related outputs at industry conferences since 2022

Market Reality Check

Price: $265.84 Vol: Volume 508,734 is below 2...

normal vol

$265.84 Last Close

Volume Volume 508,734 is below 20-day average 595,343 (relative volume 0.85x). normal

Technical Price 270.62 is trading modestly above 200-day MA 267.12, indicating a slight existing uptrend.

Peers on Argus

LH gained 1.41% while key peers were mixed: DGX -1.04%, NTRA -0.58%, MTD -0.73%,...

1 Down

LH gained 1.41% while key peers were mixed: DGX -1.04%, NTRA -0.58%, MTD -0.73%, WAT +1.43%, IQV +1.06%. Only MTD appeared in the momentum scanner, moving down without news, suggesting today’s move in LH is more company-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Digital pathology partnership	Positive	+0.9%	Expanded PathAI collaboration to deploy FDA-cleared AISight Dx platform nationwide.
Feb 17	Earnings and guidance	Positive	-2.1%	Reported 2025 growth and 2026 guidance with higher revenue and adjusted EPS.
Feb 11	Alzheimer’s test launch	Positive	+1.9%	Launched first FDA-cleared Elecsys pTau-181 blood test for Alzheimer’s assessment.
Feb 09	Board appointment	Positive	-1.1%	Appointed John H. Sampson, M.D., Ph.D., to Labcorp’s Board of Directors.
Jan 14	Dividend declaration	Positive	+3.2%	Declared quarterly cash dividend of $0.72 per share with March 12 payment date.

Pattern Detected

Recent company-specific positives (partnerships, new tests, dividends) have often seen modestly positive price reactions, while earnings and some governance events showed mild negative divergence.

Recent Company History

Over the past few months, Labcorp has reported several notable developments. On Feb 17, 2026, it posted strong 2025 results and raised 2026 guidance but saw a mild negative reaction. Earlier, it launched an FDA‑cleared Alzheimer’s blood test and expanded its digital pathology partnership with PathAI, both followed by modest gains. A new board appointment in early February drew a small decline, while a $0.72 quarterly dividend declared on Jan 14, 2026 coincided with a stronger positive move. Today’s Illumina collaboration fits the pattern of strategic, precision‑medicine‑oriented partnerships.

Market Pulse Summary

This announcement highlights an expanded collaboration between Labcorp and Illumina to broaden acces...

Analysis

This announcement highlights an expanded collaboration between Labcorp and Illumina to broaden access to precision oncology testing using NGS-based CGP and WGS, including tissue and liquid biopsy assays. A study of more than 7,600 NSCLC samples found actionable variants in over 72% of tumors, underscoring clinical relevance. In recent months, Labcorp has advanced digital pathology, launched new diagnostics, and reported strong 2025 results. Investors may track how this collaboration translates into broader test adoption, payer coverage, and additional clinical evidence.

Key Terms

next-generation sequencing (ngs), in vitro diagnostic (ivd), comprehensive genomic profiling (cgp), whole-genome sequencing (wgs), +4 more

8 terms

next-generation sequencing (ngs) medical

"advance precision oncology through innovative applications of next-generation sequencing (NGS)"

A laboratory technique that reads the sequence of DNA or RNA by processing millions of fragments at once, like scanning many pages of a book simultaneously instead of one at a time. It matters to investors because it accelerates and lowers the cost of genetic testing, drug discovery and diagnostics, expanding markets for biotech, diagnostics equipment and data services and enabling products that can change clinical care and revenue streams.

in vitro diagnostic (ivd) medical

"in vitro diagnostic (IVD) tests for comprehensive genomic profiling (CGP)"

In vitro diagnostic (IVD) tests are medical tests run on samples such as blood, urine or swabs outside the body to detect diseases, measure biomarkers or guide treatment decisions. Investors pay attention because IVDs generate recurring sales for test kits and instruments, are heavily influenced by regulatory approval, reimbursement and accuracy, and can quickly shift market value when a test becomes widely adopted or replaced — like a trusted household tool that professionals rely on every day.

comprehensive genomic profiling (cgp) medical

"IVD tests for comprehensive genomic profiling (CGP) and whole-genome sequencing"

Comprehensive genomic profiling is a lab test that reads a tumor’s DNA to find all meaningful genetic changes that could influence treatment. Think of it like scanning a building’s blueprint to spot repairable faults and the right tools to fix them; for investors, CGP matters because it can expand the pool of patients who qualify for targeted drugs, boost the value of companion diagnostics, and speed clinical trial success and regulatory approvals.

whole-genome sequencing (wgs) medical

"comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS)"

Whole-genome sequencing reads the complete set of an organism’s DNA—the full biological instruction manual—by determining the order of all its genetic letters. For investors, it matters because it is the most comprehensive tool for discovering disease causes, developing precise diagnostics and targeted therapies, and enabling new product and service markets; outcomes affect drug pipelines, regulatory risk, reimbursement potential, and long-term revenue opportunities.

liquid biopsy medical

"liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

companion diagnostic (cdx) medical

"opportunities for companion diagnostic (CDx) development, supporting both tissue"

A companion diagnostic (CDx) is a medical test designed to identify which patients are likely to benefit from, or be harmed by, a specific drug or therapy—think of it as a key that shows which locks a particular medicine can open. For investors, a CDx matters because it shapes how many patients can use the drug, affects regulatory approval and reimbursement odds, and reduces commercial and clinical risk by targeting treatment to the right people.

non-small cell lung cancer (nsclc) medical

"researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples"

A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.

biomarker medical

"improve access to critical biomarker testing for patients with cancer"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

"By deepening our collaboration, we'll continue to leverage the strengths of our respective teams to innovate and improve access to critical biomarker testing for patients with cancer," said Traci Pawlowski, vice president of Clinical Product Development at Illumina. "Our longstanding collaboration is rooted in a shared vision to advance precision oncology through groundbreaking research and leading-edge technologies."

New test development is expected to span advanced oncology research and in vitro diagnostic (IVD) tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS). These solutions will aim to address areas of unmet needs in precision oncology and help bridge existing testing gaps.

As part of the collaboration, the companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive for solid tumor profiling. Together, these distributed IVD test kits are intended to expand access to both tissue and liquid biopsy testing for hospitals and community health systems—bringing advanced biomarker testing closer to patients and helping to provide more specific diagnoses and identify eligibility for targeted treatments and clinical trials. This distributed offering also aims to provide pharmaceutical companies with differentiated opportunities for companion diagnostic (CDx) development, supporting both tissue and liquid biopsy needs for targeted therapy approvals.

"This collaboration reflects Labcorp and Illumina's shared commitment to improving cancer care through innovation and access," said Shakti Ramkissoon, MD, PhD, MBA, vice president and medical lead for oncology at Labcorp. "Building on our longstanding medical and scientific collaborations and our ongoing efforts to generate clinical evidence and expand access to advanced genomics, we are combining our expertise to deliver transformative testing solutions that support more timely, equitable cancer care."

Illumina and Labcorp will also continue joint efforts to demonstrate the clinical utility of CGP and promote its adoption. In a collaborative study published in Frontiers of Oncology, researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples. The study applied Illumina CGP to demonstrate its coverage and utility in detecting known and novel genomic features of NSCLC. Results showed that CGP detected variants with a current targeted therapy or clinical trial in more than 72% of patient tumors.

This is one of eight joint publications in oncology between Illumina and Labcorp since 2022, along with 18 posters and presentations made at industry conferences.

"Expanding access to advanced genomic testing is essential to delivering personalized cancer care," said Pawlowski. "Together with Labcorp, we are accelerating innovation to bring critical insights closer to patients and enable better outcomes across diverse care settings."

Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts 

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

View original content:https://www.prnewswire.com/news-releases/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing-302716715.html

SOURCE Illumina, Inc.

FAQ

What did Labcorp (LH) and Illumina announce on March 18, 2026 about precision oncology testing?

They announced an expanded collaboration to develop distributed IVD kits, CGP and WGS tests, and evidence-generation efforts to broaden access to biomarker testing. According to Labcorp and Illumina, the plan includes co-commercialization exploration for specific FDA-authorized and FDA-approved assays.

How will the proposed co-commercialization affect Labcorp (LH) testing availability in hospitals and community systems?

The co-commercialized distributed IVD kits aim to bring tissue and liquid biopsy testing closer to patients in hospitals and community systems. According to the companies, this is intended to increase local access to advanced biomarker testing and support diagnosis and trial eligibility.

What did the joint study between Labcorp and Illumina find about NSCLC genomic profiling?

The collaborative study evaluated more than 7,600 NSCLC tumor samples and found CGP detected variants linked to targeted therapy or trials in over 72% of tumors. According to the companies, this supports CGP's coverage and clinical utility in NSCLC.

Will the expanded Labcorp (LH) and Illumina collaboration guarantee payer coverage for new oncology tests?

No, payer coverage is not guaranteed; the collaboration aims to generate evidence to facilitate coverage but uncertainty remains. According to Labcorp and Illumina, they will pursue studies and data to support reimbursement decisions over time.

What are the main risks investors should note about the Labcorp (LH) and Illumina collaboration announced March 18, 2026?

Key risks include challenges in research, development and product launches, and reliance on partner performance in multiparty collaborations. According to the companies, these factors could cause actual outcomes to differ materially from forward-looking expectations.